Corcept Therapeutics presented the final overall‑survival data from its pivotal Phase 3 ROSELLA trial at the Society of Gynecologic Oncology (SGO) annual meeting in San Juan, Puerto Rico, on April 10, 2026. The data, which were also published in The Lancet, show a 35 % reduction in the risk of death and a 4.1‑month median overall‑survival benefit for patients with platinum‑resistant ovarian cancer treated with relacorilant plus nab‑paclitaxel versus nab‑paclitaxel alone.
The trial met both of its primary endpoints, overall survival and progression‑free survival, and demonstrated a statistically significant benefit that confirms the clinical advantage that underpinned the March 25, 2026 FDA approval of relacorilant (Lifyorli) in combination with nab‑paclitaxel. The safety profile of the combination was comparable to nab‑paclitaxel monotherapy, with no increase in adverse events, supporting its tolerability in a heavily pre‑treated population.
The FDA approval makes relacorilant the first selective glucocorticoid receptor antagonist approved for platinum‑resistant ovarian cancer and has been added to the NCCN Guidelines as a preferred regimen. The data reinforce Corcept’s position as a leading developer of selective glucocorticoid receptor antagonists and provide a robust evidence base for future regulatory submissions and market expansion beyond its established Cushing’s syndrome platform.
Bill Guyer, Corcept’s Chief Development Officer, said the positive findings affirm the company’s confidence that selective glucocorticoid receptor antagonists can benefit patients whose tumors express the glucocorticoid receptor. He added that the FDA approval enables the company to focus on delivering the therapy to patients and continuing research in other solid tumors that express the receptor across multiple treatment settings.
The ROSELLA trial was conducted in collaboration with major oncology groups, including the Gynecologic Oncology Group (GOG) and the European Network of Gynecological Oncological Trial groups (ENGOT). The robust survival benefit, coupled with a favorable safety profile, positions relacorilant as a strong addition to the limited treatment options for platinum‑resistant ovarian cancer and supports Corcept’s broader oncology strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.